A study on cost effectiveness of bariatric surgery for morbid obesity

A study on cost effectiveness of bariatric surgery for morbid obesity - Cost effectiveness of bariatric surgery

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032578

Enrollment

220

Registered

2018-06-18

Start date

2018-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid obesity

Interventions

Surgery(laparoscopic sleeve gastrectomy) Medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Morbid obesity individuals with BMI 35 or higher with or without diabetes mellitus For surgical treatment group, patients who underwent laparoscopic sleeve gastrectomy using public health insurance

Exclusion criteria

Exclusion criteria: Treatable secondary obese patients. Pregnant women or patients who may be pregnant. Patients who can not obtain written consent

Design outcomes

Primary

Measure	Time frame
Medical expenses for 2 years from registration	—

Secondary

Measure	Time frame
Patient's background at registration, and QOL survey (SF-36) and utility value (EQ-5D) at registration, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months after surgery Metabolic indicators (HbA1c, presence and content of medication including antidiabetics and insulin, BMI, C peptide, history of diabetes mellitus etc.) and SBP/DBP, HR, AST, ALT, TCHO, HDL, LDL, TG, Cre etc. at registration,6 months, 12 months, 18 months, 24 months after surgery	—

Measure

Time frame

Patient's background at registration, and QOL survey (SF-36) and utility value (EQ-5D) at registration, 1 month, 3 months, 6 months, 12 months, 18 months, 24 months after surgery Metabolic indicators (HbA1c, presence and content of medication including antidiabetics and insulin, BMI, C peptide, history of diabetes mellitus etc.) and SBP/DBP, HR, AST, ALT, TCHO, HDL, LDL, TG, Cre etc. at registration,6 months, 12 months, 18 months, 24 months after surgery

—

Countries

Japan

Contacts

Public ContactYuka Kimura

Japan Community Health care Organization Shiga Hospital Department of Clinical Research Management

chiken@shiga.jcho.go.jp077-531-0580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026